Introduction
Patients who undergo total hip replacement are at high risk of developing postoperative venous thromboembolic disease.' Without prophylaxis deep vein thrombosis and fatal pulmonary embolism occur in 40-70% and 1-5% of patients respectively.2" Moreover, it has been repeatedly shown that proximal and bilateral thrombi are much more common after total hip replacement than after general surgery. "" This high risk has led to the widespread application of prophylactic measures in hip surgery, but considerable controversy exists about the optimal prophylactic approach. The four main considerations are: firstly, the efficacy of prophylaxis in reducing the incidence of venous thrombosis; secondly, but equally importantly, the bleeding enhancing potential of several prophylactic methods, which threatens the final outcome of the operation; thirdly, the incidence of non-haemorrhagic complications; and, finally, the complexity of giving some prophylactic methods. Subcutaneous Several studies using contrast phlebography for diagnosing deep vein thrombosis showed that subcutaneous low molecular weight heparins or heparinoids were significantly more efficacious in preventing thromboembolic complications than placebo and at least as efficacious or more efficacious than fixed doses of unfractionated heparin. The observed incidences of deep vein thrombosis varied between 10% and 19% and major haemorrhagic complications were rarely encountered. 29 Interestingly, low molecular weight heparins seem to have a particularly favourable effect in preventing proximal deep vein thrombosis. The incidences of proximal deep vein thrombosis after hip replacement in studies using low molecular weight heparins and systematic phlebography in all patients were 4%, 7 .5%,56 6-5%,'9 and 6 5%"' with enoxaparin; 2-4%) and 0%21 with Fragmin; 3-6%" with Fraxiparine; and 8%27 and 4 8%12 with Lomoparan.
These favourable results, as well as the simple mode of administration, prompted us to compare treatment with a low molecular weight heparin and treatment by the efficacious but demanding "titrated dose heparin" method." As lethal pulmonary embolism is thought to be due to migration of proximal thrombi, '4 the study design took into account primarily the expected incidences of proximal deep vein thrombosis. 28 participating European departments of orthopaedic surgery. The following eligibility criteria were applied: body weight between 45 kg and 100 kg, age over 40 years, normal results on Doppler examination of the lower extremities, and having the operation under general anaesthesia. In all, 700 patients (63%) were excluded before randomisation for reasons specified a priori in the protocol (table I) . Hence 409 patients were randomised, by using a balanced assignment for each centre (by the sealed envelope method), to either titrated doses of unfractionated heparin thrice daily or low molecular weight heparin once daily. The study protocol was approved by the ethical committees of all the participating centres.
COMPOUNDS AND ASSAYS
A single batch of the low molecular weight heparin Fraxiparine (CY 216, Sanofi-Choay Laboratory, Paris) was used. It had an anti-factor specific activity of 27 Ila units (tested against the fourth international heparin standard) and an anti-factor Xa activity of 89 IU/mg when compared with the international standard for low molecular weight heparins.35 It was supplied as a concentrated solution containing 25 000 Institute Choay units (ICU)/ml, corresponding to 10 400 IU/ml and supplied in phials containing 0-6 mi.36 The unfractionated heparin was a sodium salt of 10000 IU/ml of heparin (Sanofi-Choay) supplied in ampoules containing 1 ml.
Blood was collected four hours after the morning injection into a Diatube H (Diagnostica Stago, Asnieres, France) containing 0-1 volume of citric acid (0-11 mol/ 1), theophylline (15 mmol/l), adenosine (3 7 massive wound haematoma leading to hypovolaemic shock, myocardial infarction, and death. No significant differences were observed between the two groups with respect to transfusion requirements, the incidence of wound haematomas, loss of blood through the drain, and haemoglobin concentrations before surgery or during the postoperative period. Haematomas at the injection site were significantly more common in those receiving unfractionated heparin than in those receiving low molecular weight heparin (62 v 26, p=0 001). ,-w... Plasma anti-factor Xa activities were measured only in patients receiving low molecular weight heparin. Mean anti-factor Xa activities four hours after injection were between 0 25 IU/ml and 0 29 IU/ml during the first three postoperative days and increased to between 0-33 IU/l and 0-37 IU/l in the second period (table VI) .
There seemed to be no accumulation of the drug and mean (SD) anti-factor Xa activities were not significantly different in the patients with (n= 18) and without (n=139) deep vein thrombosis (0 36 (0-24) IU/mi v 0-32 (0-15) IU/ml; p=0-46).
FOLLOW UP
Of the 394 patients operated on who were alive at the end of the initial 10 day study period, 334 (85%) were available for a follow up examination 30-50 days after discharge from hospital. Antithrombotic prophylaxis was not given in only 12-3% of these patients after phlebography and discontinuation of the two trial drugs. In 87-7% of patients the investigators maintained for an average of four to six weeks some form of prophylaxis such as continuation of subcutaneous unfractionated heparin or low molecular weight heparin, oral anticoagulation with vitamin K antagonists, aspirin, or combinations of these. One patient receiving low molecular weight heparin with a history of severe angina pectoris died 24 days after discharge from hospital; necropsy was not performed. Of the patients receiving unfractionated heparin four developed deep vein thrombosis and one had a pulmonary embolism, which was recorded by angiography.
Discussion
Over the past 20 years many prophylactic measures have been proposed to reduce the high rate of thromboembolic complications after elective total hip arthroplasty. The simplest treatments (aspirin, subcutaneous unfractionated heparin in fixed doses, dextran, and dihydroergotamine heparin) have limited efficacy or produce secondary effects precluding their general use. The more effective methods (vitamin K antagonists, intermittent pneumatic compression, adjusted doses of unfractionated heparin)22"2' 2443 are rarely used because they are difficult to give. 45 We compared the efficacy and safety of the rather cumbersome method of individually adjusting the eight hourly dose of unfractionated heparin according to the activated partial thromboplastin time21-24 with the simpler method of giving one daily weight adjusted dose of low molecular weight heparin. The total incidence ofdeep vein thrombosis on phlebography was slightly higher (16%) in those receiving unfractionated heparin than in those receiving low molecular weight heparin (12 6%). Although this difference was not significant, it indicates a 27% greater risk of developing thrombi in the patients receiving unfractionated heparin (relative risk= 1-27, 95% confidence interval 0 75 to 2 12) (table IV). In an intention to treat analysis all patients with missing, unilateral, or uninterpretable phlebograms were counted as having deep vein throm-bosis. In this analysis the incidence of deep vein thrombosis was the same in both groups (28-8% v 29 0%) . From these data we conclude that prophylaxis with low molecular weight heparin is no worse than that with the best previously available method-that is, individual adjustment of the unfractionated subcutaneous heparin dosage according to the partial thromboplastin times four hours after the morning injection.
The most noteworthy aspect of our study is the very low incidence of proximal deep vein thrombosis in patients receiving low molecular weight heparin compared with those receiving unfractionated heparin (2-9% v 13-1%, p<0 001). Patients receiving the adjusted heparin doses thus had a four to five times greater risk of proximal thrombi than those receiving low molecular weight heparin (relative risk=4 58, 1 78 to 11 76). Patients with proximal deep vein thrombosis have at least a 35% chance of developing pulmonary embolism, as evidenced by perfusion-ventilation scanning."'6 Thus the fourfold reduction in incidence of proximal deep vein thrombosis in our patients receiving low molecular weight heparin may be related to the low risk of clinically apparent pulmonary embolism in this group. Indeed, four patients receiving unfractionated heparin experienced clinically apparent pulmonary embolism compared with only one patient receiving low molecular weight heparin (this difference was not significant, but the number of events was small). All of these patients had deep vein thrombosis of the iliofemoral veins.
The incidence of major bleeding complications and all other measurements of blood loss were comparable between the two groups. Many orthopaedic surgeons are concerned that the prophylactic administration of small doses of subcutaneous heparin might result in a higher incidence of serious wound haematomas or of postoperative bleeding or in an increase of the blood transfusion requirement. Yet studies where prophylaxis with low molecular weight heparin was compared with placebo showed no differences in any of these variables.2R2726
In one recent study, which used fairly large doses of enoxaparin twice daily (corresponding to a daily dose of 6000 IU of low molecular weight heparin twice a day) a significant increase in the plasma anti-factor Xa activity six hours after the morning injection was observed from day 1 to day 14 We conclude that the low molecular weight heparin Fraxiparine, with the dose adjusted for body weight and given subcutaneously once a day, is at least as efficacious and safe in the prevention of total deep vein thrombosis after elective hip replacement as individually adjusted unfractionated heparin given thrice daily. In addition, the low molecular weight heparin was significantly more efficacious in preventing deep vein thrombosis of proximal veins and is simpler to use than unfractionated heparin.
ONE HUNDRED YEARS AGO
There has been much, and not unnaturally hostile, criticism on the refusal of the Government of India to interfere in a case of this barbarous practice in India on the ground that it was a case of voluntary suffering. It consists in suspending the volunteer devotee by means of two hooks inserted into the muscles of the back, which is supposed to propitiate the goddess of evil practices. The same practice was very common, and is to this day practised, among the American and Canadian Indians as part of the education of the brave, and of the ceremonies of the annual dances and solemn festivities. It has long been practised in the Indian "Reservations," where the degenerate remnants of the red man find the last home of his dwindling race. Till lately it was a frequent custom to make parties of pleasure to witness these ceremonies. Quite lately the missionaries and local superintendents have been persuading most of their Proteges to give up the practice, but not, we believe, with uniform success. In India the devotee is usually narcotised with "bhang" (Indian hemp), and suffers but little pain but much damage. Among the American tribes this is not the case, and the extent of the pain and the fortitude with which it is endured is the measure of the brave's courage and manhood, and one of his titles to future honour and respect.
(British MedicalJ7ournal 1891 ;ii: 1109)
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